Amendments to the Claims

The following listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1-105. (Canceled)

106. (Currently amended) A method for transporting a non-steroidal anti-inflammatory drug through intact human or animal skin or mucous membranes, comprising administering to the skin or a mucous membrane of a human or an animal a vesicular composition ~~comprising~~ consisting essentially of:

(a) a vesicle consisting essentially of:

i) one or more phosphatidyl cholines;

ii) a salt of one or more non-steroidal anti-inflammatory drugs; and

iii) one or more antioxidants,

wherein a buffer ~~an aqueous medium~~ is contained within the vesicle; and

(b) the buffer ~~aqueous medium~~,

wherein the vesicle is capable of penetrating through a permeability barrier having at least one constriction, and the vesicle is larger than the constriction by more than a factor of 2 and less than a factor of 4.

107-111. (Canceled)

112. (Previously presented) The method of claim 106, wherein at least one of the one or more phosphatidyl cholines is a natural phosphatidyl choline.

113. (Previously presented) The method of claim 112, wherein at least one of the one or more phosphatidyl cholines is from egg, soybean, coconut, olive, saffron, sunflower, linseed, whale fat, primrose, or primula.

114. (Previously presented) The method of claim 106, wherein at least one of the one or more phosphatidyl cholines is a synthetic phosphatidyl choline.

115. (Previously presented) The method of claim 106, wherein at least one of the one or more non-steroidal anti-inflammatory drugs is diclofenac or ibuprofen.

116-117. (Canceled)

118. (Previously presented) The method of claim 106, wherein the antioxidant is probucol, tocopherol, BHT, ascorbic acid, or desferroxamine.

119. (Canceled)

120. (Previously Presented) The method of claim 106, wherein up to 50 mg of the vesicular composition are administered per cm^2 of skin surface.

121. (Previously presented) The method of claim 106, wherein the salt is a lithium, sodium, potassium, cesium, rubidium, ammonium, monomethyl, dimethyl, trimethylammonium or ethylammonium salt.

122. (Previously presented) The method of claim 106, wherein the vesicle has a size of 75 to 400 nm.

123. (Previously presented) The method of claim 122, wherein the vesicle has a size of 100 to 200 nm.

124. (Currently amended) A method for transporting a non-steroidal anti-inflammatory drug through intact human or animal skin or mucous membranes,

comprising administering to the skin or a mucous membrane of a human or an animal a vesicular composition consisting essentially of ~~comprising~~:

(a) a vesicle consisting essentially of:

i) one or more phosphatidyl cholines;

ii) a salt of one or more non-steroidal anti-inflammatory drugs;

iii) one or more antioxidants; and

iv) one or more consistency modifiers and/or one or more stabilizers,

wherein a buffer an aqueous medium is contained within the vesicle; and

(b) the buffer ~~aqueous medium~~,

wherein the vesicle is capable of penetrating through a permeability barrier having at least one constriction, and the vesicle is larger than the constriction by more than a factor of 2 and less than a factor of 4.

125-128. (Canceled)

129. (Previously presented) The method of claim 124, wherein at least one of the one or more phosphatidyl cholines is a natural phosphatidyl choline.

130. (Previously presented) The method of claim 124, wherein at least one of the one or more phosphatidyl cholines is from egg, soybean, coconut, olive, saffron, sunflower, linseed, whale fat, primrose, or primula.

131. (Previously presented) The method of claim 124, wherein at least one of the one or more phosphatidyl cholines is a synthetic phosphatidyl choline.

132. (Previously presented) The method of claim 124, wherein at least one of the one or more non-steroidal anti-inflammatory drugs is diclofenac or ibuprofen.

133. (Previously presented) The method of claim 124, wherein the consistency modifier is a hydrogel.

134. (Previously presented) The method of claim 124, wherein the stabilizer is phenol, cresol, or benzyl alcohol.

135. (Previously presented) The method of claim 124, wherein up to 50 mg of the vesicular composition are administered per cm^2 of skin surface.

136. (Previously presented) The method of claim 124, wherein the salt is a lithium, sodium, potassium, cesium, rubidium, ammonium, monomethyl, dimethyl, trimethylammonium or ethylammonium salt.

137. (Previously presented) The method of claim 124, wherein the vesicle has a size of 75 to 400 nm.

138. (Previously presented) The method of claim 124, wherein the vesicle has a size of 100 to 200 nm.